Search clinical trials for: ORGN001 (formerly ALXN1101)

Total 223 results

Origin Biosciences

Completed

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

Molybdenum Cofactor Deficiency, Type A

United States, Australia, Netherlands, United Kingdom, Tunisia
Origin Biosciences

Completed

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Molybdenum Cofactor Deficiency, Type A

United States, Spain, Israel, Norway, Turkey, United Kingdom
Alexion Pharmaceuticals

Terminated

Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Czech Republic, Italy, Poland, United Kingdom
Origin Biosciences

Completed

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Molybdenum Cofactor Deficiency (MoCD) | Rare Autosomal Recessive Disorder | Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

United States
IWK Health Centre
McGill University; Canadian Institutes of Health Research (CIHR); University... and other collaborators

Active, not recruiting

Strongest FamiliesTM Neurodevelopmental

Neurodevelopmental Disorders | Behavior Disorders

Canada
GlaxoSmithKline

Completed

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Solid Tumours
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families (Formerly Family Help Program): Pediatric Anxiety (FHP-ANX)

Anxiety Disorder

Canada
Reneo Pharma Ltd

Terminated

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Primary Mitochondrial Myopathy

Spain, Australia, Belgium, Denmark, Canada, United Kingdom, France, Germany, Hungary, Italy, Netherlands, New Zealand
Digital Diagnostics, Inc.
The Emmes Company, LLC

Completed

A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy

Diabetic Retinopathy
Cinclus Pharma AG

Completed

Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation (BA)

Pharmacokinetics | Bioavailability | Safety

Slovenia
BrainQ Technologies Ltd.

Terminated

Efficacy of EMF BCI Based Device on Acute Stroke

Acute Stroke

India
Leap Therapeutics, Inc.

Completed

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Multiple Myeloma | Non-Small Cell Lung Cancer | Solid Tumors

United States
NOCwatch International
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Clinical Evaluation of a Wireless Monitoring Device to Reduce Falls in the Elderly and Others at High Risk of Falling

Injuries | Fractures | Accidental Falls

United States
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families Ontario (Formerly the Family Help Program) (SF-ON)

Oppositional Defiant Disorder | Behaviour Disorder

Canada
Orinove, Inc.
Fosun Pharma

Active, not recruiting

Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

Effect of Drug

China
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Columbia University
TG Therapeutics, Inc.

Terminated

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Reneo Pharma Ltd

Completed

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders

United States, France, Spain
Orinove, Inc.
Vanderbilt University

Active, not recruiting

Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States
Ore Pharmaceuticals, Inc.

Unknown

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

Canada, India
Reciprocal Labs
California HealthCare Foundation

Completed

Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System

Asthma

United States
Hadassah Medical Organization
Nexcella, Inc

Recruiting

NXC-201 (Formerly HBI0101) Multiple Myeloma

Dose Escalation and Safety

Israel
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Upstream Bio Inc.

Completed

Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults

Healthy

United Kingdom
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Alexion Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Healthy Subjects

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
New York State Psychiatric Institute

Completed

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder (OCD)

United States
IWK Health Centre
Canadian Institutes of Health Research (CIHR)

Completed

Strongest Families (Formerly Family Help Program): Pediatric Disruptive Behaviour Disorder

Pediatric Disruptive Behaviour Disorder

Canada
Alexion

Completed

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

Healthy

United Kingdom
Alexion

Completed

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Healthy

United States
Columbia University

Terminated

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Hodgkin Disease | Lymphoma, Non-hodgkin

United States
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
Kibow Pharma

Recruiting

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

Chronic Kidney Disease stage4

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
University of Pennsylvania
Weight Watchers International

Completed

Neurocognitive Benefits of a Weight Management Program

Overweight and Obesity

United States
Shire

Completed

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Healthy Volunteers

United States
ClearLine MD

Completed

Factors Increasing Air Burden in Intravenous Tubing

Air Leakage | Air Embolism | Air Burden
vTv Therapeutics

Completed

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

Melanoma

United States, Canada
Thallion Pharmaceuticals

Terminated

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

Glioblastoma Multiforme

United States, Canada
AstraZeneca

Completed

Baxdrostat Bioavailability and Bioequivalence Study

Hypertension

United States
Reneo Pharma Ltd

Completed

A Study of the Safety of REN001 in Patients With McArdle Disease

McArdle Disease

Spain, United Kingdom
Reneo Pharma Ltd

Terminated

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Primary Mitochondrial Myopathy

United Kingdom
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
Alexion Pharmaceuticals

Terminated

Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome

Antiphospholipid (aPL)-Positive

United States, Italy, Brazil, France, Japan, United Kingdom
Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
Alexion Pharmaceuticals

Completed

Copper Balance in Healthy Participants Administered ALXN1840

Healthy

United Kingdom
Navire Pharma Inc., a BridgeBio company

Active, not recruiting

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Tumor, Solid

United States

Search clinical trials for: ORGN001 (formerly ALXN1101)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations